
The investment objective of the scheme is to seek to generate long term capital appreciation through investing in equity and equity related securities of companies benefitting directly or indirectly Pharma, Healthcare, and allied sectors. However, there is no assurance that the objective of the scheme will be achieved.
The investment objective of the scheme is to seek to generate long term capital appreciation through investing in equity and equity related securities of companies benefitting directly or indirectly Pharma, Healthcare, and allied sectors. However, there is no assurance that the objective of the scheme will be achieved.
| Issuer/Instrument | |
% to Net Assets |
|---|---|---|
| Equity & Equity related | ||
| Pharmaceuticals and Biotechnology | 70.32 | |
| Sun Pharmaceuticals Industries Ltd. | 13.96 | |
| Divi s Laboratories Ltd. | 9.25 | |
| TORRENT PHARMACEUTICALS LTD. | 4.75 | |
| ACUTAAS CHEMICALS LTD | 3.91 | |
| Cipla Ltd. | 3.67 | |
| GLAND PHARMA LIMITED | 3.04 | |
| SAI LIFE SCIENCES LIMITED | 3.04 | |
| MANKIND PHARMA LTD | 2.84 | |
| Marksans Pharma Ltd | 2.51 | |
| LAURUS LABS LTD. | 2.49 | |
| RUBICON RESEARCH LTD | 2.37 | |
| ANTHEM BIOSCIENCES LTD | 2.33 | |
| Ajanta Pharma Ltd. | 2.11 | |
| VIYASH SCIENTIFIC LTD. | 2.01 | |
| ORCHID PHARMA LTD. | 1.64 | |
| CORONA REMEDIES LIMITED | 1.60 | |
| Aurobindo Pharma Ltd. | 1.57 | |
| EMCURE PHARMACEUTICALS LIMITED | 1.57 | |
| Pfizer Ltd. | 1.16 | |
| JUBILANT PHARMOVA LIMITED | 1.15 | |
| Lupin Ltd. | 1.14 | |
| Zydus Lifesciences Limited | 1.13 | |
| INNOVA CAPTABS LTD | 1.08 | |
| Healthcare Services | 27.68 | |
| MOLBIO DIAGNOSTICS LIMITED | 4.53 | |
| MAX HEALTHCARE INSTITUTE LTD. | 4.34 | |
| PARK MEDI WORLD LIMITED (PARK HOSPITAL) | 3.36 | |
| YATHARTH HOSPITAL AND TRAUMA CARE SERVICES LTD | 3.25 | |
| Apollo Hospitals Enterprises Ltd. | 3.25 | |
| Fortis Healthcare India Ltd | 2.95 | |
| KRISHNA INSTITUTE OF MEDICAL | 2.46 | |
| RAINBOW CHILDRENS MEDICARE LTD | 1.29 | |
| Metropolis Healthcare Ltd. | 1.14 | |
| DR.Lal Pathlabs Ltd. | 1.11 | |
| Chemicals and Petrochemicals | 1.49 | |
| JUBILANT INGREVIA LTD | 1.49 | |
| Healthcare Equipment and Supplies | 0.17 | |
| LAXMI DENTAL LIMITED | 0.17 | |
| Equity & Equity related - Total | 99.66 | |
| Triparty Repo | 1.77 | |
| Net Current Assets/(Liabilities) | -1.43 | |
| Grand Total | 100.00 | |
| | ||
| Monthly SIP of Rs 10000 | Since Inception | 1 Year |
| Total amount invested (₹) | 3,30,000 | 1,20,000 |
| Total Value as on August 31, 2026 (₹) | 4,39,840 | 1,46,982 |
| Scheme Returns (%) | 21.53 | 44.28 |
| Nifty Healthcare Index (TRI) Returns (%) | 16.86 | 27.72 |
| Alpha* | 4.67 | 16.56 |
| Nifty Healthcare Index (TRI) (₹)# | 4,14,368 | 1,37,227 |
| Nifty 50 (TRI) (₹)^ | 3,38,464 | 1,18,045 |
| Nifty 50 (TRI) Returns (%) | 1.80 | -3.01 |
| Regular | Direct | |
| Growth | Rs17.0870 | Rs17.8620 |
| IDCW | Rs17.0930 | Rs17.8600 |
A) Regular Plan B) Direct Plan
Options: Growth and Income Distribution
cum capital withdrawal (IDCW) (Payout and
Reinvestment)
| Fund Manager* |
Mr. Abhishek Bisen & Mr. Dhananjay Tikariha |
| Benchmark | Nifty Healthcare Index TRI |
| Allotment date | December 11, 2023 |
| AAUM | Rs725.98 crs |
| AUM | Rs767:70 crs |
| Folio count | 37,398 |
Trustee's Discretion
| Portfolio Turnover | 28.81% |
| $Beta | 0.99 |
| $Sharpe ## | 0.93 |
| $Standard Deviation | 16.52% |
| ^^(P/E) | 53.34 |
| ^^P/BV | 7.48 |
| Large Cap | 34.88% |
| Mid Cap | 20.90% |
| Small Cap | 43.88% |
| Debt & Money Market | 0.34% |
*% of Net Asset
Initial & Additional Investment
• Rs100 and any amount thereafter
Systematic Investment Plan (SIP)
• Rs 100 and any amount thereafter
• 5 years & above
Entry Load: Nil. (applicable for all plans)
Exit Load:
• For redemption / switch out within 30
days from the date of allotment: 0.5%
• If units are redeemed or switched out on
or after 30 days from the date of allotment:
NIL
| Regular Plan: | 2.39% |
| Direct Plan: | 0.88% |


* Investors should consult their financial advisors if in doubt about whether the product is suitable for them.
For latest Riskometer, investors may refer to an addendum issued or updated on website at www.kotakmf.com